Loomis, Sayles & Company’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $138K | Sell |
255
-68
| -21% | -$38.3K | ﹤0.01% | 568 |
|
|
2026
Q1 | $192K | Sell |
323
-3,927
| -92% | -$1.96M | ﹤0.01% | 566 |
|
|
2025
Q4 | $2.07M | Sell |
4,250
-19,607
| -82% | -$9.13M | ﹤0.01% | 453 |
|
|
2025
Q3 | $10M | Sell |
23,857
-25,182
| -51% | -$8.47M | 0.01% | 357 |
|
|
2025
Q2 | $14.1M | Sell |
49,039
-43,116
| -47% | -$12.9M | 0.02% | 297 |
|
|
2025
Q1 | $28.4M | Buy |
92,155
+13,720
| +17% | +$4.7M | 0.04% | 183 |
|
|
2024
Q4 | $27.7M | Sell |
78,435
-70,046
| -47% | -$25.7M | 0.03% | 212 |
|
|
2024
Q3 | $53.2M | Sell |
148,481
-83,408
| -36% | -$28.2M | 0.07% | 125 |
|
|
2024
Q2 | $73.9M | Sell |
231,889
-20,135
| -8% | -$5.33M | 0.1% | 80 |
|
|
2024
Q1 | $57.9M | Sell |
252,024
-2,020
| -0.8% | -$456K | 0.08% | 104 |
|
|
2023
Q4 | $55.9M | Sell |
254,044
-11,255
| -4% | -$2.59M | 0.09% | 109 |
|
|
2023
Q3 | $59.9M | Sell |
265,299
-4,984
| -2% | -$1.15M | 0.1% | 95 |
|
|
2023
Q2 | $59.7M | Buy |
270,283
+11,044
| +4% | +$2.45M | 0.1% | 103 |
|
|
2023
Q1 | $58.1M | Buy |
259,239
+56,781
| +28% | +$14M | 0.1% | 104 |
|
|
2022
Q4 | $56.3M | Sell |
202,458
-1,007
| -0.5% | -$254K | 0.11% | 97 |
|
|
2022
Q3 | $42.6M | Buy |
203,465
+37,643
| +23% | +$8.42M | 0.09% | 117 |
|
|
2022
Q2 | $39.1M | Buy |
165,822
+96,169
| +138% | +$19.6M | 0.07% | 131 |
|
|
2022
Q1 | $12.5M | Sell |
69,653
-4,074
| -6% | -$776K | 0.02% | 347 |
|
|
2021
Q4 | $15.9M | Buy |
73,727
+210
| +0.3% | +$41.2K | 0.02% | 337 |
|
|
2021
Q3 | $13.6M | Sell |
73,517
-2,229
| -3% | -$439K | 0.02% | 347 |
|
|
2021
Q2 | $13.6M | Sell |
75,746
-327
| -0.4% | -$62.3K | 0.02% | 351 |
|
|
2021
Q1 | $12.7M | Sell |
76,073
-5,694
| -7% | -$949K | 0.02% | 356 |
|
|
2020
Q4 | $12.4M | Sell |
81,767
-26,964
| -25% | -$3.54M | 0.02% | 324 |
|
|
2020
Q3 | $11M | Sell |
108,731
-2,485
| -2% | -$273K | 0.02% | 307 |
|
|
2020
Q2 | $13.5M | Sell |
111,216
-1,664
| -1% | -$187K | 0.02% | 271 |
|
|
2020
Q1 | $10.7M | Buy |
112,880
+14,294
| +14% | +$1.36M | 0.02% | 272 |
|
|
2019
Q4 | $8.68M | Sell |
98,586
-778
| -0.8% | -$68.5K | 0.01% | 375 |
|
|
2019
Q3 | $7.92M | Buy |
99,364
+24,354
| +32% | +$1.96M | 0.02% | 376 |
|
|
2019
Q2 | $5.86M | Buy |
+75,010
| New | +$7.01M | 0.01% | 398 |
|
|
2018
Q1 | – | Sell |
-86
| Closed | -$13K | – | 925 |
|
|
2017
Q4 | $13K | Sell |
86
-52
| -38% | -$6.61K | ﹤0.01% | 774 |
|
|
2017
Q3 | $16K | Sell |
138
-58
| -30% | -$7.41K | ﹤0.01% | 770 |
|
|
2017
Q2 | $25K | Buy |
+196
| New | +$24.5K | ﹤0.01% | 735 |
|
|
2016
Q2 | – | Sell |
-77
| Closed | -$9K | – | 1128 |
|
|
2016
Q1 | $9K | Sell |
77
-69
| -47% | -$8.73K | ﹤0.01% | 848 |
|
|
2015
Q4 | $23K | Hold |
146
| – | – | ﹤0.01% | 782 |
|
|
2015
Q3 | $19K | Buy |
+146
| New | +$23.4K | ﹤0.01% | 858 |
|
Other funds holding UTHR
ACA
JT
Loomis, Sayles & Company's UTHR Position: Q2 2026 in Review
Loomis, Sayles & Company reduced its United Therapeutics (UTHR) stake by 21% in Q2 2026, selling an estimated $38.3K and leaving 255 shares worth $138K. The position accounts for ﹤0.01% of the portfolio, ranked #568.
Loomis, Sayles & Company first reported a position in UTHR in Q3 2015 and has held it in 35 quarters since. The position peaked at $73.9M in Q2 2024. 875 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.
- Loomis, Sayles & Company held 255 shares of United Therapeutics worth $138K as of Q2 2026.
- Loomis, Sayles & Company sold 68 United Therapeutics shares in Q2 2026, an estimated $38.3K.
- United Therapeutics made up ﹤0.01% of Loomis, Sayles & Company's portfolio in Q2 2026, its #568 holding.
- Loomis, Sayles & Company first reported a position in United Therapeutics in Q3 2015 and has held it in 35 quarters since.
- Loomis, Sayles & Company's United Therapeutics position peaked at $73.9M in Q2 2024.
- 875 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.
Based on Loomis, Sayles & Company's 13F filing for Q2 2026, filed 14 Aug 2026.